Serum level of soluble CD163 may be a predictive marker of the effectiveness of nivolumab in patients with advanced cutaneous melanoma

AMED news

AMED news - Detail

2018.11.19: Serum level of soluble CD163 may be a predictive marker of the effectiveness of nivolumab in patients with advanced cutaneous melanoma

A press release from the Japan Agency for Medical Research and Development (AMED):

Serum level of soluble CD163 may be a predictive marker of the effectiveness of nivolumab in patients with advanced cutaneous melanoma

Visit AMED website

Back to List